PMID- 28651236 OWN - NLM STAT- MEDLINE DCOM- 20180424 LR - 20220408 IS - 1950-6007 (Electronic) IS - 0753-3322 (Linking) VI - 93 DP - 2017 Sep TI - Tanshinone I alleviates insulin resistance in type 2 diabetes mellitus rats through IRS-1 pathway. PG - 352-358 LID - S0753-3322(17)31097-1 [pii] LID - 10.1016/j.biopha.2017.06.040 [doi] AB - Tanshinone I from tanshen has been used in traditional Chinese medicine for treating cardiovascular diseases and inflammatory diseases. Given the link between inflammation and Type 2 diabetes mellitus (T2DM), we suspect that tanshinone I may have a beneficial effect on T2DM. This study was to investigate the potential effects of tanshinone I on T2DM and its underlying mechanism. T2DM was thus induced in Sprague-Dawley (SD) rats using streptozotocin (STZ) and high-fat diet. It was observed that T2DM rats had higher levels of total cholesterol (TC), nonesterified fatty acids (NEFAs), total triglyceride (TG) and total low density lipoprotein cholesterol (LDL-C) compared with normal, healthy SD rats. Treatment with tanshinone I decreased these levels and lowered blood glucose level in T2DM rats. In addition, enzyme-linked immunosorbent assay (ELISA) analysis showed that T2DM rats had elevated levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6). Furthermore, Western blot analysis revealed that T2DM rats had enhanced nuclear translocation of NF-kappaB as well as elevated phosphorylation of Ser307 in IRS-1(insulin receptor substrate 1). Treatment by tanshinone I lowered the levels of IL-6 and TNF-alpha, decreased nuclear translocation of NF-kappaB as well as phosphorylation of Ser307 in IRS-1. These results demonstrated that tanshinone I could alleviate T2DM syndrome in rats. CI - Copyright (c) 2017 Elsevier Masson SAS. All rights reserved. FAU - Wei, Ying AU - Wei Y AD - School of Chinese Pharmacy, Beijing University of Chinese Medicine, No. 6 Wangjing Middle Ring South Road, Beijing, Chaoyang District 100102, China; Health Cultivation Key Laboratory of the Ministry of Education, Beijing University of Chinese Medicine, No. 11 North Third Ring Road, Beijing, Chaoyang District 100029, China; Health Cultivation Key Laboratory of Beijing, Beijing University of Chinese Medicine, No. 11 North Third Ring Road, Beijing, Chaoyang District 100029, China. FAU - Gao, Jiaqi AU - Gao J AD - School of Chinese Pharmacy, Beijing University of Chinese Medicine, No. 6 Wangjing Middle Ring South Road, Beijing, Chaoyang District 100102, China; Health Cultivation Key Laboratory of the Ministry of Education, Beijing University of Chinese Medicine, No. 11 North Third Ring Road, Beijing, Chaoyang District 100029, China; Health Cultivation Key Laboratory of Beijing, Beijing University of Chinese Medicine, No. 11 North Third Ring Road, Beijing, Chaoyang District 100029, China. FAU - Qin, Lingling AU - Qin L AD - Health Cultivation Key Laboratory of the Ministry of Education, Beijing University of Chinese Medicine, No. 11 North Third Ring Road, Beijing, Chaoyang District 100029, China; Health Cultivation Key Laboratory of Beijing, Beijing University of Chinese Medicine, No. 11 North Third Ring Road, Beijing, Chaoyang District 100029, China. FAU - Xu, Yunling AU - Xu Y AD - School of Chinese Pharmacy, Beijing University of Chinese Medicine, No. 6 Wangjing Middle Ring South Road, Beijing, Chaoyang District 100102, China; Health Cultivation Key Laboratory of the Ministry of Education, Beijing University of Chinese Medicine, No. 11 North Third Ring Road, Beijing, Chaoyang District 100029, China; Health Cultivation Key Laboratory of Beijing, Beijing University of Chinese Medicine, No. 11 North Third Ring Road, Beijing, Chaoyang District 100029, China. FAU - Wang, Dongchao AU - Wang D AD - School of Chinese Pharmacy, Beijing University of Chinese Medicine, No. 6 Wangjing Middle Ring South Road, Beijing, Chaoyang District 100102, China; Health Cultivation Key Laboratory of the Ministry of Education, Beijing University of Chinese Medicine, No. 11 North Third Ring Road, Beijing, Chaoyang District 100029, China; Health Cultivation Key Laboratory of Beijing, Beijing University of Chinese Medicine, No. 11 North Third Ring Road, Beijing, Chaoyang District 100029, China. FAU - Shi, Haoxia AU - Shi H AD - School of Chinese Pharmacy, Beijing University of Chinese Medicine, No. 6 Wangjing Middle Ring South Road, Beijing, Chaoyang District 100102, China; Health Cultivation Key Laboratory of the Ministry of Education, Beijing University of Chinese Medicine, No. 11 North Third Ring Road, Beijing, Chaoyang District 100029, China; Health Cultivation Key Laboratory of Beijing, Beijing University of Chinese Medicine, No. 11 North Third Ring Road, Beijing, Chaoyang District 100029, China. FAU - Xu, Tunhai AU - Xu T AD - School of Chinese Pharmacy, Beijing University of Chinese Medicine, No. 6 Wangjing Middle Ring South Road, Beijing, Chaoyang District 100102, China; Health Cultivation Key Laboratory of the Ministry of Education, Beijing University of Chinese Medicine, No. 11 North Third Ring Road, Beijing, Chaoyang District 100029, China; Health Cultivation Key Laboratory of Beijing, Beijing University of Chinese Medicine, No. 11 North Third Ring Road, Beijing, Chaoyang District 100029, China. Electronic address: xutunhai1357@sina.com. FAU - Liu, Tonghua AU - Liu T AD - Health Cultivation Key Laboratory of the Ministry of Education, Beijing University of Chinese Medicine, No. 11 North Third Ring Road, Beijing, Chaoyang District 100029, China; Health Cultivation Key Laboratory of Beijing, Beijing University of Chinese Medicine, No. 11 North Third Ring Road, Beijing, Chaoyang District 100029, China. LA - eng PT - Journal Article DEP - 20170624 PL - France TA - Biomed Pharmacother JT - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JID - 8213295 RN - 0 (Abietanes) RN - 0 (Insulin Receptor Substrate Proteins) RN - 0 (Interleukin-6) RN - 0 (Irs1 protein, rat) RN - 0 (NF-kappa B) RN - 0 (Tumor Necrosis Factor-alpha) RN - 03UUH3J385 (tanshinone) RN - 5W494URQ81 (Streptozocin) SB - IM MH - Abietanes/*pharmacology MH - Animals MH - Diabetes Mellitus, Experimental/chemically induced/drug therapy/metabolism MH - Diabetes Mellitus, Type 2/chemically induced/*drug therapy/metabolism MH - Diet, High-Fat/adverse effects MH - Insulin Receptor Substrate Proteins/*metabolism MH - Insulin Resistance/*physiology MH - Interleukin-6/metabolism MH - Medicine, Chinese Traditional/methods MH - NF-kappa B/metabolism MH - Phosphorylation/drug effects MH - Rats MH - Rats, Sprague-Dawley MH - Streptozocin/pharmacology MH - Tumor Necrosis Factor-alpha/metabolism OTO - NOTNLM OT - IRS-1 OT - Tanshinone I OT - insulin resistance OT - type 2 diabetes EDAT- 2017/06/27 06:00 MHDA- 2018/04/25 06:00 CRDT- 2017/06/27 06:00 PHST- 2017/03/10 00:00 [received] PHST- 2017/06/02 00:00 [revised] PHST- 2017/06/05 00:00 [accepted] PHST- 2017/06/27 06:00 [pubmed] PHST- 2018/04/25 06:00 [medline] PHST- 2017/06/27 06:00 [entrez] AID - S0753-3322(17)31097-1 [pii] AID - 10.1016/j.biopha.2017.06.040 [doi] PST - ppublish SO - Biomed Pharmacother. 2017 Sep;93:352-358. doi: 10.1016/j.biopha.2017.06.040. Epub 2017 Jun 24.